Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rank in Stocks #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Share Price
$0.11725176
Last synced: 2025-07-14
Market Cap
$481.50K
Change (1 day)
-0.20%
Change (1 year)
0.00%
Country
FR
Trade PHAXIAM Therapeutics S.A. (PHXM)

Category

Stock price history for PHAXIAM Therapeutics S.A. (PHXM)
Highest end of day price: $0.12 on 2025-07-01

Lowest end of day price: $130.13 on 2013-05-01
Stock price history of PHAXIAM Therapeutics S.A. from 2013 to 2026
Annual Stock Price Performance
Year Performance
2025 -93.43%
2024 -61.15%
2023 -4.10%
2022 -78.67%
2021 -73.09%
2020 82.18%
2019 -31.14%
2018 -67.04%
2017 59.44%
2016 -51.03%
2015 -15.90%
2014 158.90%
2013 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$517.18 32.51%
US
$857.76 31.47%
NL
$734.04 7.47%
CH
$1.07K -6.40%
KR
$257.75 13.87%
BE